ASX:ENPPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Entropy Neurodynamics Ltd
$0.031
$0.001 (3.13%)
Day Range
$0.031 – $0.031
52 Week Range
$0.025 – $0.046
Volume
987.12K
Avg Volume (10D)
561.34K
Market Cap
$50.59M
Price Chart
Market Statistics
Open$0.031
Previous Close$0.032
Day High$0.031
Day Low$0.031
52 Week High$0.046
52 Week Low$0.025
Valuation
Market Cap50.59M
Shares Outstanding1.63B
Price to Book6.48
Trading Activity
Volume987.12K
Value Traded30.60K
Bid$0.031 × 212,933
Ask$0.032 × 192,880
Performance
1 Day-3.03%
5 Day0.00%
13 Week3.23%
52 Week6.67%
YTD-3.03%
Technical Indicators
RSI (14)41.30
50-Day SMA$0.034
200-Day SMA$0.034
Latest News
Biotechnology
Entropy Neurodynamics Reports Breakthrough Results from Phase 2a TRP-8802 Study for Treating IBS
Entropy Neurodynamics announces Phase 2a TRP-8802 IBS results: 75% responders, clear gut-brain axis effect; de-risks program ahead of TRP-8803 trials.
Biotechnology
Entropy Neurodynamics' TRP-8803 Trial Shows Repeatable Psychedelic Effects in BED Study
Entropy Neurodynamics reports repeatable psychedelic effects in TRP-8803 BED trial; Cohort 2 enrollment advancing; R&D incentives boost cash runway.
Biotechnology
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
Entropy Neurodynamics (ASX: ENP) granted Australian patent for TRP8803 (IV psilocybin) for chronic pain and neuropsychiatric disorders; protection to 2042.